Meds, Mind, Body & Benefits > Research News & Studies

Biktarvy Plus Pifeltro for People With Multidrug-Resistant HIV


Jim Allen:
Very small study but good results for those with Multidrug-Resistant HIV. article

In Short:

--- Quote ---An all-oral regimen of Biktarvy plus Pifeltro maintained viral suppression in people with highly drug-resistant HIV who switched from an older combination regimen, according to a small study published in the journal AIDS.

The study included 20 men, almost all white, who had a median age of 65 years and had been living with HIV for a median of 37 years.

All participants in this open-label study switched from the Odefsey combination pill (rilpivirine/tenofovir alafenamide/emtricitabine) plus Tivicay (dolutegravir) to the Biktarvy coformulation (bictegravir/tenofovir alafenamide/emtricitabine) plus Pifeltro (doravirine).

The participants had documented resistance to protease inhibitors, nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) and/or NNRTIs but no known resistance to rilpivirine or doravirine and no K65R or T69 mutations.

At 48 weeks after the switch, 100% of participants still had a viral load below 50
--- End quote ---


[0] Message Index

Go to full version